JP2008510754A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510754A5
JP2008510754A5 JP2007528715A JP2007528715A JP2008510754A5 JP 2008510754 A5 JP2008510754 A5 JP 2008510754A5 JP 2007528715 A JP2007528715 A JP 2007528715A JP 2007528715 A JP2007528715 A JP 2007528715A JP 2008510754 A5 JP2008510754 A5 JP 2008510754A5
Authority
JP
Japan
Prior art keywords
salt
lercanidipine
acid
acid addition
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007528715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510754A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/009043 external-priority patent/WO2006021397A1/en
Publication of JP2008510754A publication Critical patent/JP2008510754A/ja
Publication of JP2008510754A5 publication Critical patent/JP2008510754A5/ja
Abandoned legal-status Critical Current

Links

JP2007528715A 2004-08-24 2005-08-22 レルカニジピンの塩 Abandoned JP2008510754A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (2)

Publication Number Publication Date
JP2008510754A JP2008510754A (ja) 2008-04-10
JP2008510754A5 true JP2008510754A5 (enExample) 2008-10-09

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007528715A Abandoned JP2008510754A (ja) 2004-08-24 2005-08-22 レルカニジピンの塩

Country Status (19)

Country Link
US (1) US7683179B2 (enExample)
EP (1) EP1799644B1 (enExample)
JP (1) JP2008510754A (enExample)
KR (1) KR20070045351A (enExample)
CN (1) CN101048379A (enExample)
AR (1) AR050467A1 (enExample)
AU (1) AU2005276619B2 (enExample)
BR (1) BRPI0514606A (enExample)
CA (1) CA2575078A1 (enExample)
EA (1) EA011773B1 (enExample)
ES (1) ES2462921T3 (enExample)
IL (1) IL180905A0 (enExample)
MX (1) MX2007002141A (enExample)
NO (1) NO20071515L (enExample)
NZ (1) NZ553127A (enExample)
PE (1) PE20060629A1 (enExample)
TW (1) TW200613275A (enExample)
WO (1) WO2006021397A1 (enExample)
ZA (1) ZA200702364B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2007257882B2 (en) 2006-06-12 2011-09-08 Secura Bio Inc. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
WO2008112313A2 (en) * 2007-03-14 2008-09-18 Teva Pharmaceutical Industries Ltd. Processes for preparing solid states of o-desmethylvenlafaxine succinate
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
KR101343027B1 (ko) 2007-11-26 2013-12-18 테바 파마슈티컬 인더스트리즈 리미티드 O-데스메틸벤라팍신 푸마레이트의 결정형
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CA3108961C (en) * 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
CN102186351A (zh) * 2008-08-01 2011-09-14 医药公司 药物组合物和用于稳定药物组合物的方法
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CA2795023A1 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
US20250304540A1 (en) * 2022-05-10 2025-10-02 Myrodia Therapeutics Co., Ltd. 2-methyl-2-thiazoline salt

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5767136A (en) 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
WO2004035051A1 (en) * 2002-10-16 2004-04-29 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Similar Documents

Publication Publication Date Title
NZ553127A (en) L-lactic, saccharin, cinnamic, salicyclic, benzenesulphonic and naphthalene-1,5-disulphonic acid addition salts of lercanidipine
JP2004534870A5 (enExample)
NZ307946A (en) (R)-(Z)-1-azabicyclo[2.2.1]heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl]oxime maleate as a pharmaceutical agent useful for the alleviating pain and /or treating the symptoms of cognitive impairment
US6613906B1 (en) Crystal modification
CA2525700A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
CN112624983B (zh) 一种含烷基结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN103459392B (zh) 一种制备培美曲塞盐的方法
WO2003080606A8 (en) Process for preparing a pharmaceutically active compound (granisetron)
ES2296964T3 (es) Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares.
JP2005521751A (ja) アムロジピンニコチネート及びその製造方法
AU2004213104A1 (en) Indazolamides with analgesic activity
WO2006035433A3 (en) Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
CA2570795A1 (en) Process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
JP2008524183A5 (enExample)
McMahon Crystal engineering of novel pharmaceutical forms
WO2005023769A1 (en) Process for the preparation of amlodipine salts
JP2006500337A5 (enExample)
TWI443100B (zh) 培美曲塞鹽的製法
KR100914691B1 (ko) 도네페질 또는 그의 제조용 중간체의 제조방법
WO2006090263A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
US20100081824A1 (en) Processes For the preparation of different forms of (S)-(+)-Clopidogrel besylate
KR20130033242A (ko) 클로피도그렐의 공결정
AU2007227919B2 (en) Pharmaceutical composition containing clopidogrel camphorsulfonate or polymorphic forms thereof
WO2004096770A1 (en) Process for preparing almodipine mesylate monohydrate
DE60219837D1 (de) Kristalline form von quinapril hydrochlorid und verfahren zu dessen herstellung